Southridge Minerals, Inc. ( PINK:SRGE) reached up 53.13% in morning trading to $.0049 with 24M shares traded. Southridge Minerals, Inc. is a U.S.-based mineral exploration company dedicated to acquiring and developing mineral resources in geologically permissible and politically stable areas of the world. The Company seeks out early stage opportunities with good mineralization indicators that exhibit significant blue-sky potential. Southridge pursues and advances these projects that are or will be of interest to mid-size and major producers. By forming alliances on individual projects, the Company expects to develop its interests in mines operated by its partners, allowing it to continue to build value through continued exploration. Southridge is currently focused on projects in Mexico. Southridge Minerals, Inc. ( PINKSHEETS:SRGE ) announce high grade gold-silver results from their 2012 diamond drill program at their Cinco Minas, in Jalisco, Mexico. Assay results from the first six drill holes at Cinco Minas have indicated bonanza-grade silver with an average of 648 g/t (Ag) and high-grade gold of 268 g/t (Au) intercepts.
Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) reached up 11.11% in morning trading to $.70 with 250K shares traded. Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) announced that final efficacy data from its Phase 2 trial of PV-10 in patients with Stage III-IV melanoma will be presented, including response rate and time-to-event (progression free survival "PFS" and overall survival), at the ESMO 2012 (European Society for Medical Oncology) Congress in Vienna, Austria on October 1, 2012.
Augme Technologies, Inc. (OTCBB:AUGT) reached up 11.31% in morning trading to $.935 with 250K shares traded. Augme® Technologies, Inc. provides strategic services and mobile marketing technology to leading consumer and healthcare brands. Selling its products and services under the Hipcricket brand, Augme's platform has provided measurable successes across an industry-leading 200,000+ campaigns for its clients, which include many of America's brand-name leaders (e.g., Macy's, MillerCoors, Nestle, Clear Channel) in a variety of industries, along with their agencies. Augme Technologies, Inc. (OTCBB:AUGT) announced that Robert F. Hussey has been appointed Interim Chief Executive Officer of parent company Augme Technologies, Inc. and its wholly-owned subsidiary, Hipcricket, Inc., effective immediately. Mr. Hussey is a member of Augme's Board of Directors and previously served as Augme's Interim COO from June 21, 2012 to September 4, 2012.
For a detailed quote on any of the following companies, or to read the full news articles visit PennyTrader.com
About PennyTrader.com
PennyTrader.com is a financial and investor relations website committed to covering the microcap market space including Pink Sheets and OTC Bulletin Board and sub-$5 big board stocks. We strive to provide you with the best stocks alerts in the market! We focus on OTCBB, OTC, penny stocks, sub-$5 big board stocks, and timely stocks picks and alerts. Our goal is to inform you of the HOTTEST stocks in the market before they move. Our staff has years experience in the stock market, and we are confident that you’ll be impressed with the results of our stock picks! If you wish to feature your organization on our website then you can contact us at publisher@pennytrader.com.
Disclosure: PennyTrader.com is not currently being compensated for any stocks covered in this midday report.
PennyTrader.com is not a registered investment advisers or broker/dealer. PennyTrader.com makes no recommendation that the purchase of securities of companies profiled in this press release is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the micro cap companies covered and the potential lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. For our full disclaimer go to CLICK HERE
